Navigation Links
Regeneron Reports First Quarter 2013 Financial and Operating Results
Date:5/3/2013

hma later this month."

2013 Business Highlights EYLEA® (aflibercept) Injection for Intravitreal Injection

  • EYLEA is currently approved in the United States for the treatment of neovascular age-related macular degeneration (wet AMD) and macular edema following central retinal vein occlusion (CRVO).  In the first quarter of 2013, net sales were $314 million, compared to $124 million in the first quarter of 2012, and $276 million in the fourth quarter of 2012.
  • The Company and Bayer HealthCare collaborate on the global development and commercialization of EYLEA outside the United States, and share profits and losses from commercialization of EYLEA outside the United States except for Japan, where the Company receives a royalty on sales.  Regeneron maintains exclusive rights to EYLEA in the United States and is entitled to all profits from any such sales.
  • Bayer HealthCare commenced sales of EYLEA for the treatment of wet AMD in the fourth quarter of 2012 following receipt of regulatory approvals in the European Union, Japan, Australia, and other regions.  In the first quarter of 2013, Bayer HealthCare recorded net sales of EYLEA outside of the United States of $65 million, compared to $19 million in the fourth quarter of 2012.  Our share of profits (including royalties on sales in Japan) for EYLEA was $19 million, and after repaying $13 million in development expenses, we recognized $6 million in net profit from EYLEA sales outside the United States in the quarter.
  • Launches in additional countries are anticipated to continue throughout 2013 as regulatory and pricing approvals for EYLEA for the treatment of wet AMD are achieved.
  • Applications for marketing authorization for EYLEA for the treatment of macular edema following CRVO are also pending in Europe, Japan, and other regions.
  • Regeneron and Bayer HealthCare are conducting Phase 3 trials, VISTA-DME and VIVID-DME,
    '/>"/>

  • SOURCE Regeneron Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related biology technology :

    1. Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence
    2. Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
    3. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
    4. Regeneron Announces March 2012 Investor Conference Presentations
    5. Regeneron Announces Presentation at the Leerink Swann 2012 Global Healthcare Conference
    6. Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
    7. Agendia Reports More Than 20,000 MammaPrint Breast Cancer Recurrence Results
    8. PAREXEL International Reports Third Quarter Fiscal Year 2013 Results
    9. Cytos Biotechnology Ltd Reports First Quarter 2013 Financial Results and Recent Development
    10. InterMune Reports First Quarter 2013 Financial Results and Business Highlights
    11. Cord Blood Banking Industry: 2013 Growth Opportunities Analysis in New Market Research Report at ReportsnReports.com
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... , Dec. 23, 2014 Sigma-Aldrich ... that the waiting period under the Hart-Scott-Rodino Antitrust ... acquisition expired on December 22, 2014, thereby completing ... requirement for the acquisition of the Company by ... antitrust clearance satisfies another condition to closing the ...
    (Date:12/22/2014)... 22, 2014 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: ... focused on the development of autologous cell therapies, announced ... University of Calgary in conjunction with co-authors from Kyoto ... validates the company,s ongoing clinical research using dermal sheath ... baldness. The paper entitled " Hair Follicle ...
    (Date:12/22/2014)... ITRA Global, one of the largest organizations ... estate, has further expanded its global reach with the ... Western Australia, reports Mylinda Vick, CCIM, Chairman of the ... / ACORPP (Australian Corporate Property and Projects) , is ... services to a wide range of clients in the ...
    (Date:12/19/2014)... , Dec. 19, 2014 Naurex Inc., ... novel drugs for diseases of the central nervous system, ... and chief executive officer, will present at the 33 ... presentation will take place at 3:00 p.m. PST on ... in San Francisco, Calif. ...
    Breaking Biology Technology:Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2
    ... The bread and butter of Wisconsins economic growth will ... capital to transfer our best technology to the marketplace, ... and ensuring theres a 21st century infrastructure in place ... side to the equation, too, that may prove as ...
    ... a provider of supply chain execution (SCE) ... supplier compliance and inbound productivity by providing ASN ... Link and CatalystConnect SL are part of ... OAG (Open Application Group) XML interface standards. The ...
    ... WI Governor Jim Doyle today announced his "Grow ... of the recommendations is to increase broadband and ... , ,Mike Tye, AT&T regional vice present of ... encouraged by the "Grow Wisconsin" initiative unveiled today ...
    Cached Biology Technology:Athletics, pop culture and the arts 2Athletics, pop culture and the arts 3Software Enables Suppler Customer Data Integration 2
    (Date:12/22/2014)... 2014 Research and Markets ... of the "The Global Watermarking and ... http://photos.prnewswire.com/prnh/20130307/600769 ... of the global digital media watermarking and ... monitor piracy by securely and invisibly embedding ...
    (Date:12/19/2014)...  23andMe, Inc., the leading personal genetics company, today ... differences in genetic ancestry of individuals from across ... immigrants first arrived more than four hundred years ago, ... as a meeting place for peoples from different continents. ... mixing of peoples with African, European, and American origins ...
    (Date:12/17/2014)...  HITLAB SM announced today its completion ... confirm its adherence to current U.S. Food and ... to conduct regulated smart device and smart phone ... safety and research quality. "HITLAB is ... delivery with innovative technology," said Laura Pugliese ...
    Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2
    ... Scientific progress in Huntington,s disease (HD) relies upon the ... the disease,s genetics and/or pathophysiology. Large animal models, such ... rodent models, including a larger brain that is amenable ... more human-like neuro-architecture. Three articles in the latest issue ...
    ... to osteoporosis are a major cause of disability or premature ... who have already suffered one fragility fracture; they are at ... others who have not fractured. Nevertheless health care ... these patients, leaving them exposed to debilitating and life-threatening secondary ...
    ... and wild plants has concluded they are under threat ... decline or loss could have profound environmental, human health ... services to about 75% of crop species and enable ... Pollination services provided by insects each year worldwide are ...
    Cached Biology News:Large animal models of Huntington's disease offer new and promising research options 2Large animal models of Huntington's disease offer new and promising research options 3Large animal models of Huntington's disease offer new and promising research options 4New review sets international standards for best practice in fracture liaison services 2Cocktail of multiple pressures combine to threaten the world's pollinating insects 2
    Mouse anti-JNK (PT183/185) Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
    TRIAL SIZE Anti-Kaede [2F4] Monoclonal Research Focus: tag Storage: -20C Shipping Temperature: 4C...
    AANAT [Arylalkylamine N-acetyltransferase; EC 2.3.1.87]...
    TUP1 Market Segment: Molecular Biology...
    Biology Products: